Celltrion (068270) 🔎 In-depth
KOSPI · Price as of 2026-11-12 · Metrics 2026-11-13 · In-depth research 2026-11-07
Celltrion develops and manufactures biosimilars (antibody drugs built to match the efficacy of originals whose patents have expired) and markets them in Europe, the US and other regions through its own sales network; most of its revenue comes from biologics such as Remsima, Yuflyma and Omlyclo. In Q3 2026 (preliminary), revenue was ₩1.5755 trillion and operating profit ₩525.3 billion, up 53% and 74% from a year earlier, setting a record for quarterly operating profit. However, a non-operating loss of about ₩422.1 billion left net profit attributable to owners of the parent (the portion belonging to Celltrion shareholders) at just ₩75 billion. The key point now is this: if the current trend holds — new products rising to 67% of biologics revenue, Omlyclo launching in the US in October, and operating profit landing within the company's planned range for three straight quarters — the picture is strong. But if a stronger won coincides with falling prices for new US products, net profit and margins could both come under pressure.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
Data sources
Prices & market cap from the FSC securities price API (data.go.kr) · filings & financials from OpenDART (FSS) · listings from the Korea Exchange.
Prices as of 2026-11-12. Methodology is public on the methodology page.
30-second brief
Auto-extracted from the computed values.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “CDMO & Biosimilars” (Biotech & Pharmaceuticals), a type typically read first through forward P/E.
CDMO and biosimilar players see future utilization and profit hinge on large capacity build-outs and new supply contracts. Because it is the earnings still to come — reflecting fresh orders and added capacity — that drives the price, forward P/E, based on expected earnings, is the first lens.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 17.0% year over year, and the pace is slowing (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 36.0% higher than a year earlier.
- ROE is 7.2% (controlling-interest basis). It is above the sector average.
- Operating margin is 30.0%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2015-12-31
Largest shareholder Celltrion Holdings 19.41% (corporate)
Controlling bloc incl. related parties 21.6%
With the controlling bloc holding 22%, control is maintained but the free float is relatively large.
🔎 In-depth analysis Reading
Celltrion develops, manufactures and markets biosimilars (medicines built to match the efficacy and safety of biologic drugs whose patents have expired). It produces them at plants in Korea and the US, and in Europe, the US and other markets it supplies hospitals and insurers through its own sales network, without middleman distributors. Nearly all revenue comes from biologics. Of Q3 2026 (preliminary) revenue of ₩1.5755 trillion, biologics accounted for ₩1.3599 trillion, or 86.3%. The remaining ₩215.6 billion consisted of contract manufacturing (producing drugs on behalf of other pharmaceutical companies) at ₩128.5 billion, chemical drugs and others at ₩73.2 billion, and other items at ₩13.9 billion. Within biologics, newer products are driving growth. Q3 new-product revenue was ₩905.8 billion, 67% of biologics revenue, while the three early products — Remsima, Truxima and Herzuma — brought in ₩454.1 billion. The new-product share has climbed steadily from 42% in Q3 2024 and 54% in Q3 2025. Between Q3 2025 and Q3 2026, as this share rose from 54% to 67%, the operating margin also improved from 29.3% to 33.3%, making new products the main lever lifting margins. The company expects the new-product share to reach the 70% range in Q4. By product, Q3 revenue was led by Remsima (an intravenous treatment for autoimmune diseases) at ₩267.5 billion, followed by Remsima SC (the subcutaneous version) at ₩218.6 billion, Yuflyma (a Humira biosimilar) at ₩183.2 billion, Truxima (for blood cancers and other conditions) at ₩139.8 billion and Omlyclo (a Xolair biosimilar for asthma and chronic hives) at ₩132.1 billion. The five products launched in 2025 (Steqeyma, Stoboclo/Osenvelt, Avtozma, Omlyclo and Eydenzelt) generated combined Q3 revenue of ₩388.0 billion, more than four times the ₩89.2 billion of a year earlier. Omlyclo launched in the US in October 2026 as the country's first Xolair biosimilar. Zymfentra, a subcutaneous version of Remsima, was approved in the US through the new-drug pathway rather than as a biosimilar. The money comes mainly from Europe and the US. By region (based on the location of the sales subsidiary), H1 2026 revenue was ₩1.1478 trillion in Europe (45%), ₩695.3 billion in Korea and ₩477.4 billion in North America (19%). North America more than tripled from ₩154.5 billion in the same period a year earlier. US demand hinges on getting onto insurance formularies (lists of covered drugs), because prescriptions grow only once a drug is listed by pharmacy benefit managers (companies that manage drug prices and coverage lists on behalf of insurers) and insurers. In October, the company said it signed an exclusive supply agreement for Omlyclo and Avtozma with a large US healthcare company, securing preferred-drug status in place of the originals (the drugs from the original developers). In Europe, national and hospital-level tenders determine volumes. The company said its share of European prescription volume in Q2 was 30% for Omlyclo and 70% for the Remsima family (based on market research data the company cited). Production is handled by Plants 1–3 in Korea (313 batches a year on a half-year basis; a batch is one production run cultured at a time) and the drug-substance plant in Branchburg, New Jersey, acquired in December 2025 (it makes the active drug solution before it is turned into injectables; 66,000 liters). The Branchburg plant manufactures products for Eli Lilly under contract, adding new contract manufacturing revenue of ₩274.7 billion in Q1–Q3 2026. The company is expanding Branchburg by 75,000 liters to a total of 141,000 liters (up to ₩700 billion) and building Plants 4 and 5 in Songdo with 180,000 liters of capacity (₩1.2265 trillion, slated for completion by end-2030). From Q1 2027, supply will also begin under a contract manufacturing deal signed with another global pharmaceutical company (₩294.9 billion, up to ₩375.4 billion). The next products are lined up as well. The company plans to increase its commercialized biosimilars from 11 in 2026 to 18 by 2030 and 41 by 2038. Currently, CT-P55 (Cosentyx) is under regulatory review in Korea, Europe and the US; CT-P51 (Keytruda), CT-P44 (Darzalex) and CT-P53 (Ocrevus) are in Phase 3 (the last large-scale trial before approval); and CT-P52, CT-P45 and CT-P68 are in Phase 1 (small early-stage trials). Beyond biosimilars, three antibody-drug conjugates (drugs that attach a payload to an antibody to deliver it directly to cancer cells) are in clinical trials; the obesity candidate CT-G32 is scheduled to apply for clinical trials in Q1 2027 after preclinical results at end-2026, and CT-P77 is set to apply at end-2026 (per the company's Q3 earnings presentation). There are no out-licensing deals (licensing its own technology to others); instead, there are several in-licensing deals bringing in outside candidates. These include the first Kaigene deal in November 2025 (up to $744 million, of which $8 million upfront, with royalties — usage fees proportional to sales — of 5–10% of net sales), the KG013 deal in October 2026, and a deal for PinotBio's antibody-drug conjugate platform (up to $1.2428 billion, with ₩1 billion upfront). Amounts beyond the upfront payments are contingent and are paid by Celltrion only if development, approval and commercial conditions are met.
The latest close is ₩209,500 and the market capitalization is ₩48.6 trillion. The price sits above its 20-day moving average (₩198,130) and above its 60-day moving average (₩189,127). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 64.4, a neutral level. The one-month change is +16.5%, the three-month change is +4.2%, and the position relative to the 52-week high is -15.7%. Relative strength versus the KOSPI is 71 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 71% of all stocks. Over the past three months it outpaced the index by 17.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
In Celltrion's field — contract manufacturing and biosimilars — the first metric to check is the forward P/E (the share price as a multiple of this year's expected earnings). Because earnings swing considerably from year to year with new launches and capacity additions, this year's earnings show the company's real earning power better than last year's. This year's expected net profit attributable to owners of the parent, combining Q1–Q3 results with a Q4 estimate, is ₩1.2571 trillion. Dividing the ₩49.9 trillion market cap by this figure gives a forward P/E of 38.72x. The P/E based on last year's final earnings (the share price as a multiple of one year's earnings) is 46.17x, and using trailing-12-month (Q4 2025–Q3 2026) attributable net profit of ₩1.3198 trillion, it is 33.4x. Since operating profit for Q1–Q3 this year (₩1.2989 trillion) already exceeds last year's full-year total (₩1.1685 trillion), last year's multiple does not capture current earning power. There is a reason the forward multiple is slightly higher than the trailing-12-month one. This year's net profit fully includes the Q3 non-operating loss of about ₩422.1 billion. By contrast, Q4 of last year, which falls within the trailing 12 months, was a quarter in which net profit (₩527.9 billion) exceeded operating profit (₩475.2 billion). As a result, multiples measured against operating profit come out lower. Enterprise value (EV) makes this gap clear. Net debt (total borrowings minus cash) was ₩2.5997 trillion as of September 30, per the company's earnings presentation: borrowings of ₩3.7551 trillion minus cash and equivalents of ₩1.1554 trillion. Adding this to the November 3 market cap gives an EV (the price of acquiring the entire company, debt included) of about ₩46.6703 trillion. EV/EBIT (enterprise value as a multiple of operating profit) is 26.3x on trailing-12-month operating profit of ₩1.7741 trillion and 24.6x on this year's expected operating profit of ₩1.8990 trillion. EV/Sales (enterprise value as a multiple of revenue) is 8.6x, and EV/EBITDA (a multiple of operating profit before depreciation and amortization) is about 22.5x. The enterprise value metrics near the top of this page show net cash (−₩1.1192 trillion) with borrowings left out, and use operating profit for the 12 months through Q1, so they differ from this calculation. Cash generation is still weak relative to earnings. Trailing-12-month free cash flow (cash earned from operations minus spending on facilities and development) was ₩548.8 billion, and the FCF yield (free cash flow ÷ market cap) against the November 3 market cap is 1.25%. Income tax paid in H1 this year was ₩37.3 billion, less than a year earlier (₩212.4 billion), so even this figure may be temporarily inflated. Cash will continue to flow out for Songdo Plants 4 and 5 (₩1.2265 trillion) and the US plant expansion (up to ₩700 billion). The roughly ₩500 billion of share repurchases decided this year is similar in size to trailing-12-month free cash flow. As a result, net debt rose from ₩2.4534 trillion at the end of last year to ₩2.5997 trillion at end-September. The debt burden itself is not heavy. The debt ratio (liabilities relative to equity) was 31.2% as of September 30. Net debt is about 1.3x trailing-12-month EBITDA, and interest coverage (operating profit as a multiple of interest expense) is about 18x. Borrowings, however, are concentrated in the short term. At end-June, short-term borrowings were about ₩3.4269 trillion and long-term borrowings about ₩387.2 billion, so rising rates would quickly increase refinancing costs. ROE (how much the company earns on its equity in a year) is about 7.6% on a trailing-12-month basis. That is low compared with the operating margin (32.6% over the trailing 12 months). The reason is that equity swelled after the late-2023 merger, and about 60% (₩13.6893 trillion) of the ₩22.9147 trillion in total assets at end-September is intangible assets. In its corporate value-up plan, the company set a goal of ROE of 7% or more by 2027, a level it has already reached on a trailing-12-month basis. P/B (the share price as a multiple of book net assets) is 2.52x based on equity of ₩17.4677 trillion as of September 30. There are accounting points to note as well. Of H1 R&D spending of ₩284.3 billion (11.19% of revenue), ₩158.3 billion (55.7%) was booked as an intangible asset (capitalized development costs) rather than an expense. That can make earnings in a given year look better than cash spending, and if the development strategy changes and a trial is dropped, this asset could be written off as an expense all at once. In terms of amount, shareholder returns come far more from share repurchases than from dividends. The 2025 year-end dividend was ₩750 per share (dividend yield of 0.4%, ₩164.0 billion in total), while share repurchases decided this year total about ₩500 billion cumulatively. On August 31, the company disclosed a medium- to long-term policy of returning one-third of consolidated net profit through cash dividends and share cancellations. Only cancellations of shares acquired from 2026 onward count toward this formula. Not all repurchased shares are being cancelled, however. Shares acquired in June, those acquired from September 30 to October 16, and those under the October 26 decision have not yet been slated for cancellation; the company said it will choose between cancellation and a larger dividend after hearing shareholders' views at the regular shareholders' meeting in March 2027.
Starting with the long view, revenue has grown steadily over five years: ₩1.8934 trillion (2021) → ₩2.2840 trillion (2022) → ₩2.1764 trillion (2023) → ₩3.5573 trillion (2024) → ₩4.1625 trillion (2025), an average annual increase of 21.8%. The big jump in 2024 largely reflects the late-2023 merger with Celltrion Healthcare, which had handled distribution; after the merger, overseas sales were booked as revenue of a single company. Operating profit went ₩744.2 billion (2021) → ₩647.2 billion (2022) → ₩651.5 billion (2023) → ₩492.0 billion (2024) → ₩1.1685 trillion (2025), dipping once before recovering. In 2024, the revaluation of inventory taken over in the merger was charged to cost of sales and weighed on profit; as that burden eased, profit rebounded sharply in 2025. For this year's quarterly results, comparing with the same quarter of last year is the fair approach, because biosimilars have a seasonal pattern in which tender volumes and shipments cluster at year-end, swelling Q4 revenue. Revenue in Q4 2025 was 29% higher than in Q3. Q1 2026 brought revenue of ₩1.1450 trillion (+36.0%) and operating profit of ₩321.9 billion (+115.4%), and Q2 ₩1.3937 trillion (+45.0%) and ₩451.8 billion (+86.3%). Q3 (preliminary) came in at ₩1.5755 trillion (+53.1%) and ₩525.3 billion (+74.3%). Revenue growth accelerated every quarter, and Q3 operating profit was a quarterly record. The Q3 operating margin was 33.3%, 4 percentage points higher than a year earlier (29.3%). For Q1–Q3 combined, revenue was ₩4.1142 trillion (+45.3%) and operating profit ₩1.2989 trillion (+87.4%). Operating profit has already exceeded last year's full-year total. It also landed within the quarterly operating profit plan the company disclosed in March (Q1 in the ₩300 billion range, Q2 in the ₩400 billion range, Q3 in the ₩500 billion range) in all three quarters. Growth is coming from new products and the US. Q3 revenue from the five products launched in 2025 was ₩388.0 billion, up 335% from a year earlier (₩89.2 billion). Omlyclo's cumulative Q1–Q3 revenue was ₩320.5 billion, more than six times the same period last year (₩49.9 billion). H1 North American revenue rose from ₩154.5 billion a year earlier to ₩477.4 billion. Contract manufacturing revenue, which did not exist last year, added ₩274.7 billion in Q1–Q3. Net profit did not grow as much as operating profit. In Q3, a non-operating loss of about ₩422.1 billion opened up between operating profit of ₩525.3 billion and pre-tax profit of ₩103.2 billion, leaving attributable net profit at only ₩75 billion (−77.4%). The company's materials offer no explanation, and the Q3 quarterly filing has not yet been released. Over the same quarter, quarter-end won/euro and won/dollar rates fell about 13% (a stronger won), and other comprehensive income (gains and losses booked directly to equity without passing through the income statement) also declined (−₩563.4 billion), apparently from translation differences at overseas subsidiaries — which points to a foreign-currency translation effect. Whether impairments or valuation losses (charges that write down asset values as expenses) are mixed in, however, has not been confirmed. This kind of gap is not new. In Q2 2025, other expenses of ₩189.4 billion, including ₩85.6 billion of foreign-exchange-related losses, pushed pre-tax profit down to ₩52.4 billion. In the end, Q1–Q3 attributable net profit was ₩791.4 billion, up 58% from the same period last year (₩501.2 billion). The full-year outlook was built up quarter by quarter. To operating profit for the confirmed Q1 and Q2 and the preliminary Q3 (₩1.2989 trillion), ₩600 billion — the low end of the company's planned Q4 range in the ₩600 billion band — was added, putting full-year operating profit at ₩1.8990 trillion (+62.5%). Q4 is set at the low end of the plan because October's average won/euro and won/dollar rates were about 8% and 6% lower than in Q3, respectively, which weighs on revenue and margins once converted into won. Year-end seasonality, Omlyclo's US launch and the company's guidance for a new-product share in the 70% range in Q4 are supportive factors. Reflecting Q4 non-operating items (about −₩60 billion) and taxes, this year's attributable net profit comes to ₩1.2571 trillion (+22.1%), and the forward P/E calculated on this figure is 39.74x. Net profit growth is far lower than operating profit growth because the Q3 non-operating loss is fully included. On revenue, the company has said it will exceed its plan (₩5.3 trillion), and Q1–Q3 has already reached 77.6% of that figure.
Disclosures over the past three months fall into four strands: earnings, the US launch, a reshaping of the pipeline and shareholder returns. On earnings, the company first disclosed preliminary Q3 results on October 12 (revenue of ₩1.5 trillion and operating profit of ₩510 billion), then revised them upward on October 27 to revenue of ₩1.5755 trillion and operating profit of ₩525.3 billion. The same revised disclosure also revealed pre-tax profit of ₩103.2 billion and attributable net profit of ₩75 billion, making the non-operating loss a new issue. These figures have not yet been reviewed by the external auditor, and the cause can be confirmed in the quarterly filing, which is due by mid-November. In the US, Omlyclo launched in October as the country's first Xolair biosimilar. On October 26, the company said it had become a preferred drug through an exclusive supply arrangement for Omlyclo and Avtozma with a large US healthcare company. It added that formulary negotiations with several large pharmacy benefit managers are in the final stage and that it anticipates contracts within Q4. Even if contracts are signed, however, formulary listings mostly take effect from January 2027, so the Q4 contribution will be limited to early launch volumes. In the pipeline, development paths have shifted. CT-P51 (a Keytruda biosimilar) ended its European Phase 3 trial early on July 14. On August 21, the company then applied for Korean approval using Phase 1 pharmacokinetic data (data comparing how the drug is absorbed and cleared in the body against the original; 228 participants), and on September 5 it received approval to change the US Phase 3 trial to 220 participants. The company described this as a strategic adjustment to changes in biosimilar clinical regulation. For CT-P44 (a Darzalex biosimilar), changes reducing Phase 3 enrollment from 486 to 394 participants were approved in Korea (September 4) and Europe (September 18). Zymfentra won approval in the US, Korea and Europe for a Phase 3 trial (296 participants, 52 weeks) to extend its indications (the conditions a drug may be used for) to rheumatoid arthritis. CT-P55 (a Cosentyx biosimilar) has completed approval filings in Korea (June), Europe (July 24) and the US (July 30) and is awaiting review. On October 22, the company signed a deal to in-license KG013, an antibody drug candidate for immune diseases, from Kaigene in the US (up to $580.5 million; detailed terms undisclosed). On shareholder returns, the company disclosed a medium- to long-term policy (one-third of consolidated net profit) on August 31 and decided on share repurchases totaling about ₩500 billion across five rounds this year. On September 30, it cancelled 544,299 shares, reducing the share count to 232,072,877. Competitors were active too. Samsung Bioepis filed for US approval of its Keytruda biosimilar at the end of October, a step ahead of Celltrion. On November 3, it disclosed a US marketing agreement with major generic drugmaker Teva for its infliximab (the same ingredient as Remsima) biosimilar. On governance, a large-shareholding disclosure on October 27 confirmed that the largest shareholder, Celltrion Holdings, and its related parties hold 33.19% (77,367,199 shares), of which 23,890,067 shares (10.25% of all shares) are tied up in arrangements such as stock-backed loans.
First, the points worth watching. One, the improvement in operating profit has been confirmed in the numbers. Operating profit for Q1–Q3 came in at ₩321.9 billion, ₩451.8 billion and ₩525.3 billion, landing within the quarterly plan ranges the company disclosed in March all three times. The Q4 plan is in the ₩600 billion range, and no revision has been disclosed. If Q4 lands in this range, full-year operating profit would be ₩1.8989–1.9988 trillion, up more than 60% from last year. Two, the products driving profit have changed. The new-product share has risen to 67%, and Omlyclo, which still faces few competitors, debuted in the US in October. Prices tend to hold up for ingredients with little competition. Consider the payment limits the US government publishes each quarter for Medicare, the public health insurance program for older Americans (the drug-price benchmark Medicare pays, reflecting actual transaction prices with a lag of about six months): for infliximab, which has only three biosimilars in the US, the limit for Inflectra (Remsima's US brand name) is 45% higher for October 2026 than for July 2025. If formulary agreements with large pharmacy benefit managers are signed within Q4, US volumes of Omlyclo and Avtozma could grow from January 2027. Three, a production base that hedges against US tariffs is already running. A US presidential proclamation on April 2 imposed tariffs on imported patented drugs (15% for Korean products), but biosimilars are currently exempt. Output from the Branchburg plant counts as US-made, so it stays outside tariffs even if the exemption narrows. The more originator companies expand US production to avoid tariffs, the more contract manufacturing demand this plant will see. Indeed, following Eli Lilly volumes, supply for another global pharmaceutical company begins in Q1 2027. Four, the barriers to development have come down. In October 2025, the US Food and Drug Administration issued draft guidance saying comparative efficacy trials for biosimilars may not always be necessary. The European Medicines Agency finalized guidance in March 2026 allowing comparative efficacy studies to be waived. Celltrion's reduction of the CT-P51 trial size and its Korean filing based on Phase 1 data follow this trend. If development costs and timelines for follow-on products shrink, the plan to expand commercialized products from 11 (2026) to 18 (2030) will gain speed. Five, the multiple sits within the peer range. The forward P/E of 38.72x on this year's expected earnings is at the upper end of the large-cap Korean bio/pharma peer group (about 20–39x on this year's expected earnings), and EV/EBIT on operating profit is 24.6x. Given the pace of operating profit growth (+62.5%), it is not out of line with peers. There are clear cautions as well. One, net profit swings widely with exchange rates. The Q3 non-operating loss of about ₩422.1 billion left attributable net profit at just ₩75 billion, and the cause has not yet been confirmed by the quarterly filing. With nearly half of revenue coming from Europe (45% in H1), a falling won/euro rate squeezes both won-converted revenue and margins. The October average won/euro rate was about 11% lower than in Q4 last year. If the won stays strong, Q4 may also end up at the low end of the plan; if exchange rates reverse, the effect would run the other way. Two, prices of new US products are falling fast. For Steqeyma, in ustekinumab (Stelara), which has seven biosimilars in the US, the Medicare payment limit fell 77%, from $12.642 per mg for January 2026 to $2.890 for October. Avtozma's October figure is also 34% lower than July's. Formulary positions are won by conceding on price, so even if volumes rise, a steeper drop in unit prices would mean slower US revenue growth. Omlyclo could follow the same path once later entrants arrive. Three, competitors are ahead in the next growth products. In Keytruda biosimilars, Samsung Bioepis secured Phase 3 (555 participants) results first and filed for US approval at the end of October, while Celltrion's CT-P51 is at the US Phase 3 stage. On top of that, Merck's subcutaneous Keytruda was approved in the US and Europe in 2025, and in August 2026 it met the conditions for a sales-stage milestone payment owed to its technology provider. This means the market an intravenous biosimilar would enter is shrinking even before launch. In chronic hives, a key indication for Xolair, an oral drug (Novartis's Rhapsido) also won US approval in September 2025. Four, US drug-pricing policy could narrow price gaps from 2028. Xolair and Cosentyx are among the drugs in Medicare's third round of price negotiations (effective 2028). If original prices are cut by law, the price advantage that Omlyclo and CT-P55 can offer would shrink. Negotiated prices will be published by November 30. On the biosimilar tariff exemption, the Commerce Secretary must deliver a review on whether to expand it within one year of the proclamation, making spring 2027 the next checkpoint. Five, with more debt than cash, there are many demands on capital. Net debt was ₩2.5997 trillion at end-September, and borrowings are concentrated in the short term. With the US Federal Reserve having raised its policy rate in September and the Bank of Korea holding at 3.00% in October, rates remain high, so refinancing costs could rise. Expansions in Songdo and the US and share repurchases are proceeding at the same time, while the FCF yield is 1.25%. With intangible assets at about 60% of total assets and a large amount of development costs capitalized, there is also room for impairments if the development strategy changes. Six, 23,890,067 of the shares held by the largest shareholder's side (about 31% of their holdings, 10.25% of all shares) are tied up in arrangements such as stock-backed loans. The company also has a history of cutting its 2026 revenue plan from ₩7 trillion to ₩5.3 trillion, so it is worth keeping in mind that disclosed plans can change. In sum, operational improvement has been confirmed in line with the company's plan for three consecutive quarters, with the US launch, local production and shareholder returns building on top. The strong case is one in which Q4 operating profit holds in the ₩600 billion range, listings with large pharmacy benefit managers come through and the won stops strengthening. The weak case is one in which a stronger won and falling US unit prices combine to push the quarterly operating margin back to the Q1 level (28.1%), or the quarterly filing shows that the Q3 non-operating loss is of a recurring nature.
🔎 Valuation vs peers Fairly valued
Peers were hand-picked from large Korean bio/pharma companies that obtain approvals and market biologics directly in global markets, choosing those with the closest businesses: Samsung Epis Holdings, a dedicated biosimilar competitor (owner of Samsung Bioepis, which competes directly with Celltrion in eight molecules according to the competitor's half-year filing); Samsung Biologics, in the same sub-sector (contract manufacturing and biosimilars); SK Biopharm, which has a direct-sales structure in the US; and Yuhan, as a baseline for large traditional pharma. The sector-wide median (a P/E sample of 95 companies) includes many loss-making biotechs, so it was not used as the comparison benchmark. The P/E, P/B and ROE in the table are multiples of the latest confirmed results at the current price. Samsung Epis Holdings was only recently created through a spin-off, so its confirmed-results multiple (a P/E of 44.99x) is distorted, and it was compared on this year's expected earnings instead. On this year's expected earnings, the P/E is about 38.8x for Samsung Biologics (estimated at the same point in time), about 28.4x for Yuhan, about 21.2x for Samsung Epis Holdings and about 20.1x for SK Biopharm (the last three are July in-depth estimates converted at current market caps).
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Samsung Biologics | 37.59x | 8.47x | 23.70% |
| Samsung Epis Holdings | 100.33x | 1.43x | 1.44% |
| SK Biopharmaceuticals | 25.70x | 7.36x | 37.56% |
| Yuhan Corporation | 32.75x | 2.57x | 9.06% |
Starting with its position versus peers, the forward P/E (the share price as a multiple of this year's expected earnings) based on this year's expected attributable net profit is 39.74x. On the same basis, Samsung Biologics is about 38.8x, Yuhan about 28.4x, Samsung Epis Holdings about 21.2x and SK Biopharm about 20.1x, so the peer group spans 20–39x. Celltrion sits at the upper end of that range but below Samsung Biologics. The P/B (the share price as a multiple of book net assets) based on September 30 equity is 2.52x, well below Samsung Biologics (8.48x) and SK Biopharm (6.66x) and similar to Yuhan (2.48x). What supports the higher multiple is the pace of growth. This year's operating profit is estimated to rise 62.5% from last year, and Q1–Q3 results all landed within the company's quarterly plan ranges. The share of higher-margin new products is rising from 67% toward the 70% range, and Omlyclo's US launch and a US production base are being added. There are discount factors too. ROE (how much the company earns on its equity in a year) is about 7.6%, indicating low capital efficiency. The company is pursuing capacity expansion and share repurchases at the same time while carrying net debt of about ₩2.6 trillion. Prices of new US products are falling quickly because of competition, and net profit swings widely with exchange rates. Looking only at multiples on confirmed results would lead to the wrong conclusion. The P/E of 44.99x on last year's confirmed earnings predates this year's surge in profit and does not capture current earning power. On trailing-12-month earnings, it is 33.4x. This year's expected net profit of ₩1.2571 trillion (+22.1%) fully includes the Q3 non-operating loss of about ₩422.1 billion, so net profit growth is far lower than operating profit growth. This loss matches the size of the won's appreciation at quarter-end and appears to be a foreign-currency translation effect, but it has not yet been confirmed by the quarterly filing. As a result, the enterprise value multiple on operating profit (EV/EBIT, 24.6x on this year's estimate) comes out lower than the P/E. Overall, the stock sits in the upper part of the peer range, and its growth pace explains that position, so we view it as within the fairly valued zone. The site's default diagnostic shows 'Overvalued' because it compares against the sector median (10.52x on this year's expected earnings), which includes many loss-making biotechs; that is why it differs from this assessment.
Earnings outlook Estimate company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| Next quarter | Q4 2026 | — | ₩600.0 billion | — |
Price history Close · MA20 · MA60
The latest close is ₩209,500 and the market capitalization is ₩48.6 trillion. The price sits above its 20-day moving average (₩198,130) and above its 60-day moving average (₩189,127). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 64.4, a neutral level. The one-month change is +16.5%, the three-month change is +4.2%, and the position relative to the 52-week high is -15.7%. Relative strength versus the KOSPI is 71 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 71% of all stocks. Over the past three months it outpaced the index by 17.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +17.49% / 6M +54.11% / 12M -10.17%
Key metrics Computed vs sector median
Valuation
The P/E of 44.99x is above the sector median (13.58x). The P/B of 2.75x is above the sector median (1.04x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 7.2%, above the sector average (1.0%). The operating margin is 30.0%. The debt ratio is 30.2%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.6B | $2.7B | $3.1B | +17.01% ↓ slower |
| Operating profit | $488.3M | $368.8M | $875.8M | +137.49% ↑ faster |
| Net profit | $401.5M | $316.8M | $771.8M | +143.58% ↑ faster |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.7B | $1.6B | $2.7B | $3.1B |
| Operating profit | $557.8M | $485.1M | $488.3M | $368.8M | $875.8M |
| Net profit | $434.3M | $403.1M | $401.5M | $316.8M | $771.8M |
| Revenue CAGR | 4-yr avg 21.77% | ||||
Revenue rose 17.0% year over year (2023 ₩2.2 trillion → 2024 ₩3.6 trillion → 2025 ₩4.2 trillion), and the three-year trend is 'rising'. That said, the pace of growth slowed from the prior year. Operating profit rose 137.5% year over year. Profit is growing at an accelerating pace. Over the 5 years on record, revenue compound annual growth (CAGR) is 21.8%. The two-year revenue CAGR is 38.3%. In the most recent quarter (Q1 2026), revenue was 36.0% higher than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- Revenue grew 17.0% year over year, a sign of growth.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-11-03UpdateSamsung Bioepis discloses US marketing deal with Teva for SB2 (infliximab) and SB4 (etanercept) biosimilars — up to $420 millionA major generic distributor entering the US infliximab market — home to Remsima (US name Inflectra) and Zymfentra — with competing products is a new variable. The deal's effectiveness depends on conditions such as regulatory review. Source
- 2026-11-02UpdateZymfentra (CT-P13 SC) Phase 3 trial plan in rheumatoid arthritis approved in the US (9/23), Korea (10/14) and Europe (10/30 local time)A global Phase 3 trial with 296 participants and 52 weeks of treatment, testing superiority over placebo on ACR50 (the share of patients whose symptoms improve by 50%) at week 12. It is a step toward extending indications beyond ulcerative colitis and Crohn's disease; there are no results yet. Source
- 2026-10-30UpdateSamsung Bioepis discloses US marketing application for SB27, its Keytruda biosimilarA competitor that secured Phase 3 (555 participants) primary analysis results first has entered the US approval process, putting it ahead of Celltrion's CT-P51, which is at the US Phase 3 stage. Source
- 2026-10-27EarningsRevised Q3 2026 consolidated preliminary results — revenue ₩1.5755 trillion, operating profit ₩525.3 billion, pre-tax profit ₩103.2 billion, attributable net profit ₩75 billionRevised upward from the initial October 12 disclosure (revenue ₩1.5 trillion, operating profit ₩510 billion). With revenue up 53.1% and operating profit up 74.3% year over year, it was a quarterly record and within the Q3 plan range (the ₩500 billion range). By contrast, a non-operating loss of about ₩422.1 billion left attributable net profit down 77.4%; the cause needs to be confirmed in the quarterly filing. Source
- 2026-10-27IROmlyclo (Xolair biosimilar) launched in the US in October — Q3 revenue ₩132.1 billion, Q1–Q3 cumulative ₩320.5 billionPer the company's Q3 earnings presentation. It launched as the first omalizumab biosimilar in the US, and the company said its European prescription-volume share in Q2 was 30%. The company projects a new-product revenue share in the 70% range for Q4. Source
- 2026-10-26UpdateDecision to repurchase an additional 514,404 treasury shares (about ₩100 billion) — five repurchase decisions in 2026 totaling about ₩500 billionOn-market purchases during 2026-10-27 to 2027-01-26. The company said it will decide whether to cancel these shares after hearing shareholder views at the regular shareholders' meeting in March 2027. Treasury shares held as of October 26 total 4,531,984. Source
- 2026-10-26UpdateOmlyclo and Avtozma secure exclusive supply and preferred-drug listing with a large US healthcare companySecures a formulary channel that opens up US volumes for new products. The company said formulary negotiations with several large pharmacy benefit managers are in the final stage and anticipates contracts within Q4, with the effect coming mainly from the January 2027 formulary update. Source
- 2026-10-22UpdateIn-licensing of long-acting anti-APRIL antibody KG013 from Kaigene (US) — total deal size up to $580.5 million (about ₩769.5 billion)An antibody drug candidate for immune diseases such as IgA nephropathy. The maximum amount combines the upfront payment and development/approval and sales milestones; detailed terms were withheld from disclosure at the counterparty's request. Amounts beyond the upfront payment are contingent on meeting conditions. Source
- 2026-09-21UpdateCT-P44 (Darzalex biosimilar) Phase 3 trial plan change approved in Korea (9/4) and Europe (9/18 local time) — 394 participantsPer the company's Q3 earnings presentation, the change cuts enrollment from 486 to 394, and the company expects lower development costs. The Phase 3 trial compares against the subcutaneous original in relapsed/refractory multiple myeloma and runs for two years. Source
- 2026-09-16UpdateDecision to cancel 544,299 treasury shares (cancelled September 30) — shares outstanding 232,617,176 → 232,072,877All shares from the roughly ₩100 billion repurchase decided on August 31 (9/1–9/14, average ₩183,722) were cancelled. As a cancellation of shares acquired from 2026 onward, it counts toward the shareholder return ratio disclosed in August; it is the second such case, after shares acquired April 23–May 6 were cancelled on May 21. Source
- 2026-09-07UpdateCT-P51 (Keytruda biosimilar) US Phase 3 trial plan change approved (9/5 local time) — 220 participantsAfter the early termination of the European Phase 3 in July, the Phase 3 trial in metastatic non-squamous non-small cell lung cancer continues in the US, revised to 220 participants and a two-year treatment period. The center of gravity of development has shifted to the US. Source
- 2026-09-02UpdateNovartis signs option and license deal with Alteogen to convert multiple biologics to subcutaneous injection — up to $3.223 billionReflects a broadening shift by large originator companies from intravenous to subcutaneous injection. This points to a shrinking market for intravenous biosimilars to replicate, which ties in with Celltrion's strategy of developing subcutaneous versions. Source
- 2026-08-31UpdateMedium- to long-term shareholder return policy disclosed — return ratio of one-third of consolidated net profit (cash dividends + cancellation of treasury shares acquired from 2026 onward)Cancellations of treasury shares acquired and held before 2026 are excluded from the calculation. It is a medium- to long-term standard presented separately from the March corporate value-up plan's 'three-year average shareholder return ratio of 40% for 2025–2027'. On the same day, the company also decided to repurchase about ₩100 billion of its own shares. Source
- 2026-08-31UpdateAlteogen discloses achievement of a $25 million sales milestone for subcutaneous Keytruda (Keytruda Qlex)The originator's shift to subcutaneous injection has been confirmed in actual sales, signaling a shrinking market for an intravenous Keytruda biosimilar (CT-P51). Source
- 2026-08-24UpdateCT-P51 (Keytruda biosimilar) Korean marketing application filed (8/21) — 16 indicationsThe filing is based on Phase 1 results in melanoma patients (228 participants) showing key pharmacokinetic measures within equivalence limits. The company plans to continue filing country by country; approval outcomes are not yet known. Source
- 2026-07-30UpdateCT-P55 (Cosentyx biosimilar) US marketing application — filings completed in three regions following Korea (6/26) and Europe (7/24)Targets plaque psoriasis and other conditions. Because the original Cosentyx is in Medicare's third round of price negotiations (effective 2028), the price gap it can offer in the US after approval will be affected by the outcome. Approval outcomes are not yet known. Source
- 2026-07-14UpdateCT-P51 (Keytruda biosimilar) European Phase 3 terminated early and trial plan voluntarily withdrawnThe company said it adjusted its strategy toward smaller enrollment in line with changes in biosimilar clinical regulation. Development has since continued through the Korean filing and the revised US Phase 3. Source
- 2026-06-29UpdateSamsung Bioepis discloses equivalence confirmed in the primary analysis of its Phase 3 (555 participants) for Keytruda biosimilar SB27In the race for a Keytruda biosimilar, the competitor secured Phase 3 results first. Source
- 2026-03-24Update2026 quarterly operating profit plan disclosed (consolidated) — Q1 in the ₩300 billion range, Q2 ₩400 billion range, Q3 ₩500 billion range, Q4 ₩600 billion rangeQ1–Q3 results (₩321.9 billion, ₩451.8 billion and ₩525.3 billion) all landed within their ranges, so whether Q4 reaches the ₩600 billion range is the baseline for this year's profit. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Latest disclosure sweep (as of today) | fetch_disclosures days=200 limit=40 2026-11-02, (2026-06-04) major 10 (06-30·07-03·07-27·08-31·09-16·09-29·10-12·10-20·10-26·10-27) | (2026-11-07) . 11-02 3 3 | Confirmed | link |
| Cross-check of Q3 2026 results against source documents | revenue 1₩575.5 billion·operating profit ₩525.3 billion· ₩103.2 billion·net profit ₩78.4 billion· net profit ₩75.0 billion, 1~3 net profit ₩791.4 billion | 3 (p20)· revenue(p21) , (10-12) revenue 15,000·operating profit ₩510.0 billion | Confirmed | link |
| Quarter-by-quarter build-up of this year's estimate (forward P/E) | operating profit 3,218.7 + 4,517.9 + 5,253 + 6,000 = 1₩899.0 billion → net profit 7,914 + 4,657 = 1₩257.1 billion → 44₩70.6 billion ÷ 1₩257.1 billion = 35.1x | 4 operating profit ₩600.0 billion(2026-03-24) , revenue approx. 58 2026 revenue ₩5.3 trillion | Confirmed | link |
| Explaining the Q3 non-operating loss | −₩422.1 billion = 1,032 − operating profit ₩525.3 billion | 6 →9 / 1,767.1→₩1,539.1(−12.9%), / 1,550.9→₩1,355.4(−12.6%). 1 +₩129.3 billion·2 +₩34.0 billion(approx. 1.2%) 1% approx. ₩30.0 billion −₩385.0 billion | Unverified | link |
| Precise recalculation of the sub-sector key metric (forward P/E) | 35.1x = 44₩70.6 billion ÷ 2026 net profit 1₩257.1 billion | 26.35x | Mismatch | link |
| Cash capacity (net debt, FCF yield) | 9 2₩599.7 billion = 37,551 − 1₩155.4 billion, 12 FCF ₩548.8 billion → FCF 1.25%, ÷ EBITDA approx. 1.3x, approx. 18x | −1₩119.2 billion·FCF 0.71% | Mismatch | link |
| Metrics recalculated on the latest quarter | 4 ·9 30 PER 33.4x, PBR 2.52x·2.54x, ROE approx. 7.6%, 9 30 31.2%, 136.1%, operating margin 32.6%, net margin 24.2% | PER 40.78x·PBR 2.49x·ROE 7.19%· 30.23%·operating margin 30.03%·net margin 28.46% | Mismatch | link |
| Review of self-check flags | 14 , 0 | 1 , 2015-12-31 — 25.89%, 33.19% | Confirmed | link |
| Progress against the company's official 2026 plan | operating profit 1 ₩300.0 billion·2 ₩400.0 billion·3 ₩500.0 billion·4 ₩600.0 billion 3,218.7·4,517.9·₩525.3 billion, 1~3 revenue 4₩114.2 billion = 2026 revenue ₩5.3 trillion 77.6% | 2026 revenue ₩5.3 trillion | Confirmed | link |
| License agreement terms | . : KG013 58,050 , Kaigene 1 74,400 , 124,280 , Abpro 200 · 1,000· 17.5 | 2026-10-22 KG013 | Confirmed | link |
| Pipeline stages and timelines | CT-P55, CT-P51, CT-P6 SC. 3: CT-P51 , CT-P44, CT-P53, . 1: CT-P52·CT-P45·CT-P68 | 3 (p16·p17) | Confirmed | link |
| Contract manufacturing agreements | Eli Lilly 4.73 , 1.98 | revenue 1Q26 962·2Q26 500·3Q26 ₩128.5 billion | Confirmed | link |
| Total shares outstanding | 232,072,877 | 10 approx. 232,129,189 | Mismatch | link |
| Audit of figures in the prose (QA-1) | 6 ·· · 223 . PER 44₩70.6 billion ÷ 1₩257.1 billion = 35.06x | 3 (20261027800047)· operating profit (20260324800372)·(20261027000365)·(20260506800095·20260916800015)· (20261103800583)·(20260814003751) | Confirmed | link |
Recent filings Source
- 2026-06-04OwnershipOwnership-change filing
- 2026-06-01Large-business-group status disclosure
- 2026-05-29Corporate governance report
- 2026-05-29OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-28Disclosure
- 2026-05-21TreasuryMaterial-fact report
- 2026-05-21Material-fact report
- 2026-05-21OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15PeriodicQuarterly report
- 2026-05-12Disclosure
- 2026-05-11Paid-in capital increase (amended)
- 2026-05-11Amended filing
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.